Paper42258564
Integrated Analysis Identifies an Anoikis-Related Gene Signature for Predicting Prognosis in Patients With Triple-Negative Breast Cancer.
Xue B and 8 others. IET Syst Biol, 2026. Cited by 0 papers, by iCite.
Cite this record
ConductScience Library. Integrated Analysis Identifies an Anoikis-Related Gene Signature for Predicting Prognosis in Patients With Triple-Negative Breast Cancer. Papers, record 42258564. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/42258564
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- Integrated Analysis Identifies an Anoikis-Related Gene Signature for Predicting Prognosis in Patients With Triple-Negative Breast Cancer.
- PubMed
Topics9
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Triple Negative Breast Neoplasms | Major topic |
| Anoikis | Major topic |
| Transcriptome | Major topic |
| Humans | |
| Prognosis | |
| Female | |
| Gene Expression Regulation, Neoplastic | |
| Biomarkers, Tumor | |
| Gene Expression Profiling |
Source PubMed
Grants5
Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.
| Grant, as the record writes it | Agency | Country | NIH project | Stated by |
|---|---|---|---|---|
| KF2129-93 | State Key Laboratory of Systems Medicine for Cancer | PubMed | ||
| 22ZR1450000 | Natural Science Foundation of Shanghai Municipality | PubMed | ||
| 82272828 | National Natural Science Funds | PubMed | ||
| 2023YXNS057 | Jining Key Research and Development Plan | PubMed | ||
| 823RC563 | Hainan Provincial Natural Science Foundation of China | PubMed |
Source PubMed
References69
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 28218905 | Phosphorylation-mediated activation of LDHA promotes cancer cell invasion and tumour metastasis. | Oncogene | 2017 | https://conductscience.org/library/papers/28218905 | PubMed |
| 2 | 27184417 | Triple-negative breast cancer: challenges and opportunities of a heterogeneous disease. | Nat Rev Clin Oncol | 2016 | https://conductscience.org/library/papers/27184417 | PubMed |
| 3 | 32444850 | Visualizing and interpreting cancer genomics data via the Xena platform. | Nat Biotechnol | 2020 | https://conductscience.org/library/papers/32444850 | PubMed |
| 4 | 28129544 | Genomic and Transcriptomic Features of Response to Anti-PD-1 Therapy in Metastatic Melanoma. | Cell | 2017 | https://conductscience.org/library/papers/28129544 | PubMed |
| 5 | 33512556 | Interleukin 17A promotes cell migration, enhances anoikis resistance, and creates a microenvironment suitable for triple negative breast cancer tumor metastasis. | Cancer Immunol Immunother | 2021 | https://conductscience.org/library/papers/33512556 | PubMed |
| 6 | 18579285 | Anoikis resistance and tumor metastasis. | Cancer Lett | 2008 | https://conductscience.org/library/papers/18579285 | PubMed |
| 7 | 25887482 | Gene-expression molecular subtyping of triple-negative breast cancer tumours: importance of immune response. | Breast Cancer Res | 2015 | https://conductscience.org/library/papers/25887482 | PubMed |
| 8 | 34793275 | Biomarkers for breast cancer immunotherapy: PD-L1, TILs, and beyond. | Expert Opin Investig Drugs | 2022 | https://conductscience.org/library/papers/34793275 | PubMed |
| 9 | 32934733 | Monascin accelerates anoikis in circulating tumor cells and prevents breast cancer metastasis. | Oncol Lett | 2020 | https://conductscience.org/library/papers/32934733 | PubMed |
| 10 | 31095287 | A randomised phase II study investigating durvalumab in addition to an anthracycline taxane-based neoadjuvant therapy in early triple-negative breast cancer: clinical results and biomarker analysis of GeparNuevo study. | Ann Oncol | 2019 | https://conductscience.org/library/papers/31095287 | PubMed |
| 11 | 27260936 | Single-Cell RNA-Seq Steps Up to the Growth Plate. | Trends Biotechnol | 2016 | https://conductscience.org/library/papers/27260936 | PubMed |
| 12 | 29130882 | Simultaneous enumeration of cancer and immune cell types from bulk tumor gene expression data. | Elife | 2017 | https://conductscience.org/library/papers/29130882 | PubMed |
| 13 | 27915969 | Anoikis and EMT: Lethal "Liaisons" during Cancer Progression. | Crit Rev Oncog | 2016 | https://conductscience.org/library/papers/27915969 | PubMed |
| 14 | 31056702 | ESMO recommendations on microsatellite instability testing for immunotherapy in cancer, and its relationship with PD-1/PD-L1 expression and tumour mutational burden: a systematic review-based approach. | Ann Oncol | 2019 | https://conductscience.org/library/papers/31056702 | PubMed |
| 15 | 38868713 | Sangerbox: A comprehensive, interaction-friendly clinical bioinformatics analysis platform. | Imeta | 2022 | https://conductscience.org/library/papers/38868713 | PubMed |
| 16 | 30345906 | Atezolizumab and Nab-Paclitaxel in Advanced Triple-Negative Breast Cancer. | N Engl J Med | 2018 | https://conductscience.org/library/papers/30345906 | PubMed |
| 17 | 26363006 | A TDO2-AhR signaling axis facilitates anoikis resistance and metastasis in triple-negative breast cancer. | Cancer Res | 2015 | https://conductscience.org/library/papers/26363006 | PubMed |
| 18 | 34336660 | CAFs Interacting With TAMs in Tumor Microenvironment to Enhance Tumorigenesis and Immune Evasion. | Front Oncol | 2021 | https://conductscience.org/library/papers/34336660 | PubMed |
| 19 | 38605910 | Investigating the Immunogenic Cell Death-Dependent Subtypes and Prognostic Signature of Triple-Negative Breast Cancer. | Phenomics | 2024 | https://conductscience.org/library/papers/38605910 | PubMed |
| 20 | 31154235 | Regulators and mechanisms of anoikis in triple-negative breast cancer (TNBC): A review. | Crit Rev Oncol Hematol | 2019 | https://conductscience.org/library/papers/31154235 | PubMed |
Genes10
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
| Gene | NCBI Gene ID | Linked by | In Genes | Source |
|---|---|---|---|---|
| ASS1 | 445 | PubTator's text mining | https://conductscience.org/library/genes/445 | NCBI Gene |
| CD274 | 29126 | PubTator's text mining | https://conductscience.org/library/genes/29126 | NCBI Gene |
| COL18A1 | 80781 | PubTator's text mining | https://conductscience.org/library/genes/80781 | NCBI Gene |
| DHX36 | 170506 | PubTator's text mining | https://conductscience.org/library/genes/170506 | NCBI Gene |
| PIK3CA | 5290 | PubTator's text mining | https://conductscience.org/library/genes/5290 | NCBI Gene |
| PTEN | 5728 | PubTator's text mining | https://conductscience.org/library/genes/5728 | NCBI Gene |
| S100B | 6285 | PubTator's text mining | https://conductscience.org/library/genes/6285 | NCBI Gene |
| STC2 | 8614 | PubTator's text mining | https://conductscience.org/library/genes/8614 | NCBI Gene |
| TGFBI | 7045 | PubTator's text mining | https://conductscience.org/library/genes/7045 | NCBI Gene |
| ZEB2 | 9839 | PubTator's text mining | https://conductscience.org/library/genes/9839 | NCBI Gene |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Trials
- Comments and corrections
- Cited by
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/42258564
GET https://conductscience.org/api/papers/v1/42258564/references?page=2